Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735PRNewsWire • 06/25/25
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street AnalystsThe Motley Fool • 06/21/25
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.The Motley Fool • 06/18/25
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?The Motley Fool • 06/16/25
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover PotentialSeeking Alpha • 06/02/25
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?Zacks Investment Research • 05/27/25
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped FridayThe Motley Fool • 05/02/25